Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 3Completed 3Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Neoplasms 474Carcinoma, Non-Small-Cell Lung 449Breast Neoplasms 331Neoplasm Metastasis 243Colorectal Neoplasms 214Melanoma 213Leukemia, Myeloid, Acute 191Multiple Myeloma 180Recurrence 169Ovarian Neoplasms 169Prostatic Neoplasms 163Lymphoma, Non-Hodgkin 149Lung Neoplasms 134Pancreatic Neoplasms 125Lymphoma 124Carcinoma, Renal Cell 112Leukemia, Lymphocytic, Chronic, B-Cell 111Squamous Cell Carcinoma of Head and Neck 110Stomach Neoplasms 92Carcinoma, Hepatocellular 89Lymphoma, Large B-Cell, Diffuse 88Leukemia 88Triple Negative Breast Neoplasms 86Lymphoma, Follicular 82Head and Neck Neoplasms 79Glioblastoma 75Myelodysplastic Syndromes 70Urinary Bladder Neoplasms 68Small Cell Lung Carcinoma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

itepekimab 2dupilumab 1Broncho-Vaxom 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Dermatitis, Atopic × Clear all
NCT05222516 2023-08-08

Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD

OM Pharma SA

Phase 2 Terminated
63 enrolled
Lymphoid

Dermatitis, Atopic, Lymphoma, Follicular

NCT03738423 2022-06-10

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals

Phase 2 Terminated
129 enrolled 36 charts
Lymphoid

Dermatitis, Atopic, Lymphoma, Follicular

NCT03736967 2021-11-01

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals

Phase 2 Terminated
206 enrolled 34 charts
Lymphoid

Dermatitis, Atopic, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡